Is Zevra Therapeutics financially healthy?
Not really
Zevra Therapeutics earns only -11.3 times its interest bill, which leaves little room.
The numbers behind it
Net debt / EBITDA0.0 years
Cash vs. debt$62M vs. $63M
Current ratio4.9×Short-term assets for each $1 of bills due within a year
Interest coverage-11.3×How many times operating profit covers the interest bill
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about Zevra Therapeutics
Data as of Nov 13, 2026.